Prostate Cancer Clinical Trials in Irvine, California

6 studies are recruiting for prostate cancer in Irvine, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

   Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   City of Hope Lennar Foundation Cancer Center ( Site 0059), Irvine, California

   Locations

   298 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06925737 on ClinicalTrials.gov

2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   University of California Irvine Chao Family Comprehensive Cancer Center, Irvine, California

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

3. A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

   This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity of [225Ac]Ac-AKY-2519 in participants with metastatic castration-resistant pro…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Hoag Memorial Hospital Presbyterian, Irvine, California

   Locations

   6 in total

   Run by

   Aktis Oncology, Inc.

   See if you can join NCT07581184 on ClinicalTrials.gov

4. Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer

   This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the …

   Stage

   Not phased

   Ages

   18 and older

   Site

   City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California

   Locations

   8 in total

   Run by

   Varian, a Siemens Healthineers Company

   See if you can join NCT05804318 on ClinicalTrials.gov

5. This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

   This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   UCLA Hematology/Oncology - Irvine, Irvine, California

   Locations

   337 in total

   Run by

   Pfizer

   See if you can join NCT07028853 on ClinicalTrials.gov

6. PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

   The standard of care imaging of prostate cancer metastases recommended by the National Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be suboptimal. PyL is a novel PET tracer designed to detect prostate specific membrane antigen (PSMA) expressed on prostate c…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Hoag Memorial Hospital Presbyterian, Irvine, California

   Run by

   Hoag Memorial Hospital Presbyterian

   See if you can join NCT04700332 on ClinicalTrials.gov